Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
Novartis
Novartis
American University of Beirut Medical Center
University of Liverpool
Ascentage Pharma Group Inc.
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia
Australasian Leukaemia and Lymphoma Group
Novartis
Sumitomo Pharma America, Inc.
Pfizer
UNC Lineberger Comprehensive Cancer Center
Gruppo Italiano Malattie EMatologiche dell'Adulto
Gruppo Italiano Malattie EMatologiche dell'Adulto
Novartis
Novartis
Novartis
Pfizer
Mansoura University
Hikma Pharmaceuticals LLC
Dana-Farber Cancer Institute
Poitiers University Hospital
Fred Hutchinson Cancer Center
University of Milano Bicocca
Novartis
Imperial College London
Pfizer
M.D. Anderson Cancer Center
Heidelberg University
Norwegian University of Science and Technology
Fred Hutchinson Cancer Center
National Institutes of Health Clinical Center (CC)
Novartis
Novartis
Bristol-Myers Squibb
Dana-Farber Cancer Institute
Novartis
Novartis
Poitiers University Hospital
Hospital Virgen de la Salud
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
Novartis
Novartis
Novartis
Il-Yang Pharm. Co., Ltd.
Novartis
University of Leipzig
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Niguarda Hospital
Dong-A ST Co., Ltd.